As the year unfolds the biotech industry will look closely at these ten first-in-class drugs on track to reach FDA approval ...

Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ...

In a report released today, Jason Zemansky from Bank of America Securities maintained a Sell rating on Esperion (ESPR – Research Report), with ...